AstraZeneca Licenses Silicon Genetics' Gene Expression Enterprise Solution
Redwood City, CA. - January 15, 2002 - silicon Genetics, a leader in gene expression informatics solutions, today announced that AstraZeneca PLC has licensed its enterprise-wide products, GeneSpringTM, GeNetTM and Script EditorTM, designed for a genomics discovery platform.
Used together, GeneSpring, GeNet, and Script Editor form a comprehensive solution for the management of gene expression results, with central data storage and easy to use desktop applications. The system seamlessly integrates data analyses and storage, while promoting more efficient workflow, better handling of data, and improved communication and collaboration among researchers.
"I'm delighted that AstraZeneca has chosen our enterprise products to form a part of their corporate gene expression informatics solution," said Saeid Akhtari, Senior Vice President and Chief Operating Officer of Silicon Genetics. "Silicon Genetics' proprietary and proven informatics technology is a perfect complement to large pharmaceutical companies' gene expression data analysis and integration platforms and is an ideal solution for high-end, high throughput research environment."
"Gene expression analysis is a fundamental tool of modern drug discovery and development, and AstraZeneca expects to benefit from broader access to Silicon Genetics' informatics technology," said Dr. Kenneth Fasman, AstraZeneca's Vice President and Global Head of R&D Informatics. "We believe their products will enhance our ability to exploit our complementary investments in this area."
Other news from the department research and development
